Gynodian

Known as: Androst-5-en-17-one, 3-((1-oxoheptyl)oxy)-, (3beta)-, mixt. with (17beta)-3-hydroxyestra-1,3,5(10)-trien-17-yl pentanoate 
 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2009
2009
Objective: to reveal gender differences in brain structural changes after clinical death and to assess the neuroprotective propp… (More)
Is this relevant?
1995
1995
The aim of our study was to examine the effects of hormone replacement on the size of the uterus and the development or increase… (More)
Is this relevant?
Review
1990
Review
1990
Traditional beliefs about climacteric symptoms and widespread imaginations about unwanted effects of estrogens in the pill have… (More)
Is this relevant?
1983
1983
Clinical and metabolic effects of depot-injections of estradiol valerianate-dehydroepiandrosterone enanthate at a 1:50 ratio… (More)
Is this relevant?
1983
1983
Gynodian-Depot is well suited for treatment of the characteristic symptoms accompanying the menopause in women. The plasma levels… (More)
Is this relevant?
1981
1981
53 patients from a mainly climacteric population were treated monthly with 200 mg dehydroepiandrosterone (DHEA) oenanthate or… (More)
Is this relevant?
1979
1979
Ten weeks after total hysterectomy and bilateral salpingo-oophorectomy, nine women were treated with injections of Gynodian… (More)
Is this relevant?